Lexicon Files Investigational New Drug Application For LX2931 As A Potential Treatment For Rheumatoid Arthritis
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for LX2931, an oral drug candidate for rheumatoid arthritis and other autoimmune conditions. [click link for full article]
Rheumatologists Redesign Osteoporosis, Rheumatoid Arthritis Care
With the nation collectively spending about $18 billion per year on osteoporosis related bone fractures, Geisinger researchers found that streamlining the ordering process for osteoporosis bone density scans quadrupled the number of patients who received the exam. An estimated 10 million Americans suffer from osteoporosis. Like most providers, Geisinger Health System measures the mineral content in the bones of patients who are at high risk for osteoporosis through DXA scans. [click link for full article]
